Portfolio company Organoid Sciences completed IPO on Korea Exchange (Kosdaq) with 52.38% Day 1 surge.
MAY 2025
South Korean bio-innovation company developing organoid-based regenerative therapeutics, drug efficacy and toxicity testing, precision-medicine solutions, and organoid cultivation and manufacturing platforms
South Korean bio-innovation company developing organoid-based regenerative therapeutics, drug efficacy and toxicity testing, precision-medicine solutions, and organoid cultivation and manufacturing platforms. Its technologies use organ-like structures that replicate human organ architecture and function, supporting human-relevant research while reducing reliance on animal testing.